|MERCK VENTURES||Associate||The Netherlands|
AGNOSTIC OR PURE PLAYERS IN THE BIOTECH SECTOR: WHO IS BECOMING PROMINENT IN THE EARLY-STAGE FINANCING ROUNDS?
Jeroen Bakker, PhD, joined Novo A/S in 2018 as a Senior Associate of Novo Seeds. Previously, Jeroen worked at the corporate investment group of Merck KGaA, M Ventures, focusing on early-stage investments in US, EU and Israel. Prior to this, Jeroen was active as a consultant acquiring several millions in non-dilutive funding for biotech and translational academic research. Jeroen worked in biotech at Syntaxin Ltd (acquired by Ipsen) and published several articles on innate immunity in high-ranking journals such as Journal of Experimental Medicine while obtaining his PhD in immunology from the University of Amsterdam.